Non-invasive Contrast Enhanced Ultrasound Sonography in Intestinal Acute Graft-vs-Host Disease

University of Pisa

Status: Unknown

Conditions: Neutropenic Enterocolitis; Intestinal GVHD

Study type: Observational

Funder types: Other

Identifiers

NCT01699516

IRB33982

Details and patient eligibility

About

Intestinal acute graft-vs-host disease (GVHD) is a life-threatening complication after allogeneic hematopoietic cell transplantation. Non-invasive diagnostic procedures are still lacking and diagnosis is difficult. We hypothesized that contrast-enhanced ultrasound sonography (CEUS) could detect microcirculation changes of the bowel walls during intestinal GVHD and help to detect and monitor treatment response. We employed CEUS to prospectively evaluate intestinal GVHD in 83 consecutive transplant patients between 2008 and 2011. Fourteen /83 patients with biopsy-proven intestinal GVHD were selected as study group. Fourteen patients with biopsy-proven stomach GVHD without intestinal symptoms (N=16), normal volunteers (N=6) and patients with neutropenic enterocolitis (N=4), were chosen as control group. All patients were evaluated with both standard transabdominal ultrasonography (US) and CEUS at the onset of intestinal symptoms, during clinical follow up and at flare of symptoms. Standard US revealed non-specific bowel wall thickening, and simultaneous involvement of multiple intestinal segments in 9/14 patients. CEUS showed three distinct patterns of microcirculation changes that correlated with GVHD activity. These findings were not observed in the control group. Moreover, CEUS findings correlated with treatment response and predicted flare of intestinal symptoms. CEUS is a non-invasive, easily reproducible bed-side tool to detect and monitor intestinal GVHD.

Enrollment: 32 estimated patients

Sex: All

Ages: 22 to 66 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Bone Marrow Transplant
• intestinal acute graft versus host disease
• stomach GVHD
• neutropenic enterocolitis

Exclusion criteria

no biopsy proven intestinal or stomach GVHD no neutropenic enterocolitis

Trial design

32 participants in 2 patient groups

Intestinal graft vs host disease

Description:

Patients with biopsy-proven intestinal acute GVHD in the setting of an allogenic transplant

Control group

Description:

In the setting of an allogenic bone marrow transplant: patients with biopsy-proven stomach GVHD without intestinal symptoms and patients with neutropenic enterocolitis. Normal volunteers.